The content has been updated to reflect current best-evidence recommendations for treatment of bacterial, fungal, mycobacterial, parasitic and viral infections, newly approved drugs, new indications for existing drugs and references to new reports in the literature.
Available in print in pocket size, spiral bound and large library editions.
New material and areas of significant change in this 45th edition include:
HCV treatment (Table 14G): Expanded treatment options using the newest direct acting agents (DAA) for interferon-free therapy based on the latest guidelines.
Parasitic diseases (Table 13A): Treatment of parasitic diseases has been comprehensively updated.
Antiretroviral therapy (Table 14): New once daily single tablet regimens have been added.
Antibacterial drug information (Table 9, Table 10): Pharmacology data and adverse effects summary have been extensively updated.
Resistant Bacteria (Tables 1, 5, & 6): Updates reflect the latest data and treatment options, including new agents for treatment of resistant S. aureus.